Literature DB >> 24717884

Life-threatening angioedema induced by angiotensin-converting enzyme inhibitors: characteristics and risk factors.

Tali Stauber1, Ronit Confino-Cohen, Arnon Goldberg.   

Abstract

BACKGROUND: Angioedema induced by angiotensin-converting enzyme inhibitors (ACEIs) is a well-known phenomenon and roughly accounts for one-third of angioedema cases presenting to the emergency departments. This study aimed to characterize the patients with severe reactions that required hospitalization and tried to identify the risk factors for these life-threatening events.
METHODS: The records of all patients hospitalized with the diagnosis of "angioedema" over a 10-year period were retrospectively analyzed. Patients' characteristics as well as the characteristics of the angioedema-induced hospitalizations were studied.
RESULTS: In 46 of 165 patients (28%) the angioedema was ACEI induced. The severity of the event was mild in 12 patients (26%), moderate in 25 patients (54%), and severe in 9 patients (19%). Twelve patients (26%) were admitted to the intensive care unit and six patients (13%) underwent intubation. Epinephrine was administered to 13 patients (29%), steroids were administered to 40 patients (87%), and anti-histamines were administered to 36 patients (78%). One patient died as a consequence of the event (2%). Twenty patients (45%), including the deceased patient, had recurrent events of angioedema before admission. Obese patients had significantly more recurrent events compared with nonobese patients (p = 0.03). There was also a tendency for more severe events in the obese patients (p = 0.079). Diabetes was significantly associated with moderate-to-severe events (p = 0.009) whereas treatment with beta-blockers or diuretics was significantly associated with milder events (p = 0.007 and p = 0.044, respectively).
CONCLUSION: The high recurrence rate of ACEI-induced angioedema preceding subsequent life-threatening events suggests underdiagnosis of this potentially fatal adverse reaction. Diabetes and probably obesity are risk factors for more severe events. Physicians following patients receiving ACEI should be more aware of possible shortcomings associated with these medications.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24717884     DOI: 10.2500/ajra.2014.28.3989

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  6 in total

1.  Editorial: Insight into allergic, rhinologic and skull based pathologies.

Authors:  Jean Anderson Eloy
Journal:  Am J Rhinol Allergy       Date:  2014 Jan-Feb       Impact factor: 2.467

Review 2.  Otolaryngology in Critical Care.

Authors:  Jisha Joshua; Eric Scholten; Daniel Schaerer; Mahmood F Mafee; Thomas H Alexander; Laura E Crotty Alexander
Journal:  Ann Am Thorac Soc       Date:  2018-06

3.  Epidemiology of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record.

Authors:  Aleena Banerji; Kimberly G Blumenthal; Kenneth H Lai; Li Zhou
Journal:  J Allergy Clin Immunol Pract       Date:  2017-04-01

Review 4.  [Drug-induced angioedema : Focus on bradykinin].

Authors:  B Sachs; T Meier; M M Nöthen; C Stieber; J Stingl
Journal:  Hautarzt       Date:  2018-04       Impact factor: 0.751

5.  Fatal outcome of late-onset angiotensin-converting enzyme inhibitor induced angioedema: A case report.

Authors:  Jone Jackeviciute; Vidas Pilvinis; Rugile Pilviniene
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

6.  Angioedemas associated with renin-angiotensin system blocking drugs: Comparative analysis of spontaneous adverse drug reaction reports.

Authors:  Diana Dubrall; Matthias Schmid; Julia Carolin Stingl; Bernhardt Sachs
Journal:  PLoS One       Date:  2020-03-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.